Aripiprazole Tablet
Product Images NDC 63629-7003

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 63629-7003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (Image Fig1 Effectofotherdrug Arip)

A chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' showing aripiprazole fold change with 90% confidence intervals. The chart compares the effects of CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam) on aripiprazole's AUC and Cmax, relative to a reference without interacting drugs.*

FDA Label Image

Image 2 (Image Fig2 Effectofotherdrug Dehydroarip)

A pharmacokinetic chart titled 'The effects of other drugs on dehydro-aripiprazole pharmacokinetics,' showing fold change and 90% confidence intervals for AUC and Cmax metrics. It compares the effects of various CYP3A4 and CYP2D6 inhibitors, inducers, gastric acid blockers, and other drugs on aripiprazole metabolism relative to a reference without interacting drugs.*

FDA Label Image

Image 3 (Image Fig3 Effectofarip Otherdrug)

A pharmacokinetic chart titled 'The effects of aripiprazole on pharmacokinetics of other drugs' showing fold changes and 90% confidence intervals of various drugs when co-administered with aripiprazole. The horizontal axis indicates change relative to reference (without interacting drug) from 0.5 to 3.0. The chart lists drugs like dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, with pharmacokinetic measures (AUC, Cmax, INR, DMDRP) represented by black squares and error bars.*

FDA Label Image

Image 4 (Image Fig4 Effectofintrinsicfactor Arip)

A figure titled 'Effects of intrinsic factors on aripiprazole pharmacokinetics' showing a plot of fold change and 90% confidence intervals for aripiprazole pharmacokinetics in various special populations. The x-axis represents change relative to reference, and the y-axis lists factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Data points represent changes in AUC and Cmax values for these comparisons.*

FDA Label Image

Image 5 (Image Fig5 Effectofintrinsicfactor Dehydroarip)

A pharmacokinetic chart illustrating the effects of intrinsic factors on dehydro-aripiprazole. The graph shows fold changes and 90% confidence intervals for variables including CYP2D6 metabolism status, gender, age groups, and degrees of hepatic and renal impairment. The x-axis represents change relative to a reference value, while the y-axis lists each factor evaluated for impact on exposure (AUC) and peak concentration (Cmax) of dehydro-aripiprazole.*

FDA Label Image

Fig 6 (Image Fig6 Schizophreniastudy 5)

Kaplan-Meier plot illustrating the cumulative proportion of patients experiencing relapse over time in a schizophrenia study comparing aripiprazole and placebo. The x-axis shows days from randomization up to 182 days, and the y-axis represents the proportion with relapse. The chart includes a numeric table of subjects at risk over time for both groups.*

FDA Label Image

7 (Image Fig7 Bipolarstudy 7)

Kaplan-Meier curve showing the cumulative proportion of patients with relapse over time, comparing aripiprazole and placebo groups in a bipolar disorder study. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. The graph includes a subject risk table for both groups at various time points.*

FDA Label Image

8 (Image Fig8 Bipolarstudy 8)

Kaplan-Meier estimation chart depicting the cumulative proportion of patients with relapse to any mood event over days from randomization in Bipolar Study 8. The graph compares two groups: ABILIFY (blue solid line) and placebo (red dashed line), with the proportion of relapse on the y-axis and days from randomization on the x-axis. The number of subjects at risk for each group is shown at multiple time points below the x-axis.*

FDA Label Image

9 (Image Fig9 Tourettesdisorderstudy1)

A line graph showing least square means of change from baseline in YGTSS total tic score over 8 weeks of treatment in a Tourette's disorder study. The graph compares three groups: ARIP-LOW, ARIP-HIGH, and PLACEBO, with ARIP-HIGH showing the greatest reduction in tic scores over time.*

FDA Label Image

Image (Image Logo Medguide)

FDA Label Image

Logo (Image Logo Pi)

FDA Label Image

Description Image (Image Structure)

Chemical structure diagram of aripiprazole showing its molecular framework including chloro-substituted aromatic rings, nitrogen-containing piperazine and lactam rings, and ether linkages.*

FDA Label Image

Label (Lbl636297003)

Aripiprazole 10 mg tablet packaging label from Bryant Ranch Prepack. The label indicates the product is a round white tablet, with a package size of 30 tablets. The label includes a compare-to reference to Abilify 10 mg tablet by Torrent Pharmaceuticals Limited. Storage instructions specify room temperature of 20°-25°C (68°-77°F). NDC 63629-7003 is printed on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.